Summary

China Small Molecule CDMO Market Summary

The China small molecule CDMO market size was estimated at USD 3.71 billion in 2024 and is projected to reach USD 8.34 billion by 2033, growing at a CAGR of 9.58% from 2025 to 2033 The market is driven by rising drug discovery efforts in fields such as oncology, cardiovascular, and central nervous system, leading many pharmaceutical companies to outsource.

Besides, the small molecule CDMOs in China are characterized by favorable cost structures, a skilled workforce, and a growing range of domestic projects, further becoming appealing partners for both local and international companies. In addition, the market's expansion is fueled by the rising demand for generics and innovative small molecule therapies, further propelling the trend toward integrated, end-to-end development and manufacturing solutions. In addition, growing technological advancements in the market have played a crucial role in enhancing the capabilities of China's CDMO sector, which further supports market growth.

Besides, innovations such as process optimization, real-time monitoring via Process Analytical Technology (PAT), and machine learning applications for predictive analytics are increasingly prioritized to improve efficiency and product quality. Moreover, the integration of continuous manufacturing technologies and advanced synthetic chemistry further supports the development of high-potency and complex molecules. This technological advancement has further supported the Chinese CDMOs to compete more effectively in the global arena, particularly for early-phase and high-value niche projects.

China Small Molecule CDMO Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the China small molecule CDMO market report based on product, drug, and application.
• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Active Pharmaceutical Ingredients (API)
• Finished Drug Products
• Drug Outlook (Revenue, USD Million, 2021 - 2033)
• Innovators
• Generics
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Oncology
• Cardiovascular Disease
• Central Nervous System (CNS) Conditions
• Autoimmune/Inflammation
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Drug
1.2.3. Application
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.7.2. Value-Chain-Based Sizing & Forecasting
1.7.3. Multivariate Model Analysis
1.8. List Of Secondary Sources
1.9. List Of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. China Small Molecule CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rise in drug development pipelines
3.2.1.2. Growing reliance on CDMOS for cost-effective and specialized manufacturing services.
3.2.1.3. Capacity expansions by CDMOS
3.2.1.4. Technological advancements
3.2.2. Market Restraint Analysis
3.2.2.1. Growing demand for biologics
3.2.2.2. Complexity and challenges in the synthesis of certain small molecules, impacting manufacturing efficiency
3.3. Technology Landscape
3.4. Market Analysis Tools
3.4.1. Porter’s Five Force Analysis
3.4.2. PESTEL by SWOT Analysis
3.4.3. COVID-19 Impact Analysis
Chapter 4. China Small Molecule CDMO Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. China Small Molecule CDMO Market Product Movement Analysis
4.3. China Small Molecule CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Active Pharmaceutical Ingredients (API)
4.4.1. Active Pharmaceutical Ingredients (API) Market Estimates and Forecasts,2021 - 2033 (USD Million)
4.5. Finished Drug Products
4.5.1. Finished Drug Products Market Estimates and Forecasts,2021 - 2033 (USD Million)
Chapter 5. China Small Molecule CDMO Market: Drug Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. China Small Molecule CDMO Market Drug Movement Analysis
5.3. China Small Molecule CDMO Market Size & Trend Analysis, by Drug, 2018 to 2030 (USD Million)
5.4. Innovators
5.4.1. Innovators Market Estimates and Forecasts,2021 - 2033 (USD Million)
5.5. Generics
5.5.1. Generics Market Estimates and Forecasts,2021 - 2033 (USD Million)
Chapter 6. China Small Molecule CDMO Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. China Small Molecule CDMO Market Application Movement Analysis
6.3. China Small Molecule CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
6.4. Oncology
6.4.1. Oncology Market Estimates and Forecasts,2021 - 2033 (USD Million)
6.5. Cardiovascular Disease
6.5.1. Cardiovascular Disease Market Estimates and Forecasts,2021 - 2033 (USD Million)
6.6. Central Nervous System (CNS) Conditions
6.6.1. Central Nervous System (CNS) Conditions Market Estimates and Forecasts,2021 - 2033 (USD Million)
6.7. Autoimmune/Inflammation
6.7.1. Autoimmune/Inflammation Market Estimates and Forecasts,2021 - 2033 (USD Million)
6.8. Others
6.8.1. Others Market Estimates and Forecasts,2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.2. Company Market Share/Assessment Analysis, 2024
7.3. Company Profiles
7.3.1. Lonza
7.3.1.1. Company Overview
7.3.1.2. Financial Performance
7.3.1.3. Service Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Catalent, Inc
7.3.2.1. Company Overview
7.3.2.2. Financial Performance
7.3.2.3. Service Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Thermo Fisher Scientific Inc.
7.3.3.1. Company Overview
7.3.3.2. Financial Performance
7.3.3.3. Service Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Bellen Chemistry
7.3.4.1. Company Overview
7.3.4.2. Financial Performance
7.3.4.3. Service Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Siegfried Holding AG
7.3.5.1. Company Overview
7.3.5.2. Financial Performance
7.3.5.3. Service Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Recipharm AB
7.3.6.1. Company Overview
7.3.6.2. Financial Performance
7.3.6.3. Service Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Eurofins Scientific
7.3.7.1. Company Overview
7.3.7.2. Financial Performance
7.3.7.3. Service Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. WuXi AppTec
7.3.8.1. Company Overview
7.3.8.2. Financial Performance
7.3.8.3. Service Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. Asymchem Laboratories
7.3.9.1. Company Overview
7.3.9.2. Financial Performance
7.3.9.3. Service Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Langhua Pharmaceutical (Viva Biotech subsidiary)
7.3.10.1. Company Overview
7.3.10.2. Financial Performance
7.3.10.3. Service Benchmarking
7.3.10.4. Strategic Initiatives
7.3.11. Apeloa Pharmaceutical
7.3.11.1. Company Overview
7.3.11.2. Financial Performance
7.3.11.3. Service Benchmarking
7.3.11.4. Strategic Initiatives
7.3.12. JiuZhou Pharmaceutical
7.3.12.1. Company Overview
7.3.12.2. Financial Performance
7.3.12.3. Service Benchmarking
7.3.12.4. Strategic Initiatives


List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 China Small Molecule CDMO Market Estimates and Forecasts, by Product, 2021 - 2033 (USD Million)
Table 4 China Small Molecule CDMO Market Estimates and Forecasts, by Drug, 2021 - 2033 (USD Million)
Table 5 China Small Molecule CDMO Market Estimates and Forecasts, by Application, 2021 - 2033 (USD Million)